Marco DiBonaventura Selected Research

abrocitinib

8/2022	Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
1/2022	Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.
1/2022	Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
10/2021	Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
10/2021	Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
9/2021	Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE.
9/2021	Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
7/2021	Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
1/2021	Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
1/2020	Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marco DiBonaventura Research Topics

Disease

13	Atopic Dermatitis (Atopic Eczema) 08/2022 - 01/2020
5	Eczema 01/2022 - 01/2020
4	Ulcerative Colitis 01/2022 - 01/2021
4	Infections 01/2022 - 01/2019
3	Neoplasms (Cancer) 01/2021 - 06/2018
3	Prostatic Neoplasms (Prostate Cancer) 10/2017 - 11/2016
2	Nausea 10/2021 - 01/2021
2	Pruritus (Itching) 07/2021 - 01/2021
2	Skin Neoplasms (Skin Cancer) 01/2021 - 11/2009
2	Chorea (Rheumatic Chorea) 01/2018 - 01/2018
2	Huntington Disease (Huntington's Disease) 01/2018 - 01/2018
2	Sleep Initiation and Maintenance Disorders (Insomnia) 07/2016 - 01/2015
2	Type 2 Diabetes Mellitus (MODY) 01/2014 - 02/2011
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021
1	Hemorrhage 01/2021
1	Herpes Zoster 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Acne Vulgaris 01/2021
1	Opportunistic Infections (Opportunistic Infection) 01/2021
1	Pulmonary Embolism 01/2021
1	Gaucher Disease (Gaucher's Disease) 01/2019
1	Neoplasm Metastasis (Metastasis) 10/2017
1	Osteoporosis 07/2016
1	Hypertension (High Blood Pressure) 07/2016
1	Polycythemia Vera 01/2015
1	Bipolar Disorder (Manic Depressive Psychosis) 07/2012
1	Pain (Aches) 07/2012
1	Schizophrenia (Dementia Praecox) 07/2012
1	Communicable Diseases (Infectious Diseases) 01/2012

Drug/Important Bio-Agent (IBA)

10	abrocitinibIBA 08/2022 - 01/2020
4	Janus Kinase 1IBA 08/2022 - 01/2020
4	dupilumabIBA 01/2022 - 01/2021
3	Immunoglobulin A (IgA)IBA 10/2021 - 01/2020
2	Janus Kinase InhibitorsIBA 01/2021 - 01/2021
2	tofacitinibIBA 01/2021 - 01/2021
2	Tetrabenazine (Nitoman)FDA Link 01/2018 - 01/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	Biological ProductsIBA 12/2021
1	CytokinesIBA 10/2021
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 07/2021
1	omega-Chloroacetophenone (Mace)IBA 01/2021
1	Interleukin-13IBA 01/2021
1	Interleukin-4 (Interleukin 4)IBA 01/2021
1	SteroidsIBA 01/2019
1	Pharmaceutical PreparationsIBA 06/2018
1	CholesterolIBA 07/2016
1	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2015
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2014
1	Insulin (Novolin)FDA Link 01/2014
1	Antipsychotic Agents (Antipsychotics)IBA 07/2012
1	Aripiprazole (Abilify)FDA Link 07/2012
1	VaccinesIBA 01/2012
1	Hypoglycemic Agents (Hypoglycemics)IBA 02/2011
1	Sunscreening Agents (Sunscreens)IBA 11/2009

Therapy/Procedure

8	Therapeutics 01/2022 - 01/2018
3	Castration 10/2017 - 11/2016
1	Drug Tapering 01/2022
1	Retreatment 01/2022
1	Biological Therapy 01/2022
1	Phototherapy (Light Therapy) 01/2022
1	Subcutaneous Injections 10/2021
1	Enzyme Replacement Therapy 01/2019
1	Intravenous Administration 01/2019
1	Activities of Daily Living (ADL) 01/2018
1	Aftercare (After-Treatment) 01/2015
1	Protective Clothing 11/2009